EQS Group-Ad-hoc: Medacta Group SA / Key word(s): AGMEGM
Medacta announces the results of today's Annual General Meeting
19-May-2020 / 19:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.
*Press Release *
*Medacta announces the results of today's Annual General Meeting*
CASTEL SAN PIETRO, 19 May 2020- At today's Annual General Meeting, Medacta's
shareholders approved all proposals made by the Board of Directors.
Today's Annual General Meeting was held without the physical participation
of shareholders, in accordance with the provisions as stipulated in the
Ordinance of the Federal Council of Switzerland on the policies for
combatting the coronavirus (COVID-19-Ordinance 2). Shareholders were asked
to exercise their voting rights by giving a power of attorney and related
instructions to the independent proxy, either by returning the proxy form or
by exercising their voting rights online.
The meeting took place at Medacta's headquarters in Castel San Pietro (TI)
in the presence of the independent proxy Fulvio Pelli, Medacta's CEO,
Francesco Siccardi, Medacta's Chairman, Dr. Alberto Siccardi and the
Secretary of the Board, Donato Cortesi. A total of 17'560'829 shares were
represented by the independent proxy, representing approximately 88% of
Medacta's share capital.
At this year's Annual General Meeting, Dr. Alberto Siccardi, Maria Luisa
Siccardi Tonolli, Victor Balli and Philippe Weber were each re-elected to
the Board of Directors for another one-year term of office. In addition, Dr.
Alberto Siccardi was re-elected as chairman of the Board of Directors for
another one-year term of office. As previously communicated, Marco Gadola
decided not to stand for re-election. Medacta's shareholders also re-elected
Philippe Weber and Dr. Alberto Siccardi as members of the Remuneration
Committee, in addition to the election of Victor Balli as a new member of
the Remuneration Committee, in each case for another one-year term of
office.
Further proposals by the Board of Directors that were approved at today's
Annual General Meeting included the following:
- The approval of Management Report, the Annual Statutory Financial
Statements and the Consolidated Financial Statements for the financial year
2019
- The approval of Remuneration Report for the financial year 2019
- The approval of the appropriation of available earnings as of 31 December
2019 of Medacta Group SA for the financial year 2019
- The discharge of the members of the Board of Directors and the Executive
Management
- The re-election of the independent proxy and the auditors
- The compensation of the Board of Directors and members of the Executive
Management
*The minutes of the Annual General Meeting will be available in due course
at:*
https://www.medacta.com/EN/agm [1]
*Contact*
Medacta Group SA
Corrado Farsetta, CFO
Phone: +41 91 696 60 60
investor.relations@medacta.ch
*About Medacta:*
Medacta is an international company specializing in the design and
production of innovative orthopaedic products and the development of
accompanying surgical techniques for joint replacement, spine surgery, and
sports medicine. Established in 1999 in Switzerland, Medacta's products and
surgical techniques are characterized by innovation. Medacta is a pioneer in
developing new offerings on the basis of minimally invasive surgical
techniques, in particular its Anterior Minimally Invasive Surgery ("AMIS")
technique for hip replacements. Medacta has leveraged its orthopaedic
expertise and comprehensive understanding of the human body to develop the
sophisticated "_MySolutions_" technology, which offers surgeons highly
personalized pre-operative planning and implant placement methodologies by
creating advanced personalized kinematic models and 3D planning tools for
use in hip, knee, shoulder and spine procedures.
*Disclaimer *
This press release has been prepared by Medacta Group SA ('Medacta' and
together with its subsidiaries, 'we', 'us' or the 'Group'). The information
contained in the press release does not purport to be comprehensive and is
not to be taken as containing any securities advice, recommendation, offer
or invitation to subscribe for, purchase or redeem any securities regarding
Medacta.
*Forward-looking information*
This press release has been prepared by Medacta and includes forward-looking
information and statements concerning the outlook for its business. These
statements are based on current expectations, estimates and projections
about the factors that may affect its future performance. These
expectations, estimates and projections are generally identifiable by
statements containing words such as 'expects,' 'believes,' 'estimates,'
'targets,' 'plans,' 'outlook' or similar expressions. Although Medacta
believes that its expectations reflected in any such forward-looking
statement are based upon reasonable assumptions, it can give no assurance
that those expectations will be achieved.
End of ad hoc announcement
Language: English
Company: Medacta Group SA
Strada Regina
6874 Castel San Pietro
Switzerland
Phone: +41 91 696 6060
E-mail: info@medacta.ch, investor.relations@medacta.ch
Internet: www.medacta.com
ISIN: CH0468525222
Listed: SIX Swiss Exchange
EQS News ID: 1051243
End of Announcement EQS Group News Service
1051243 19-May-2020 CET/CEST
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=acdad2a9c03bb1e0d5f646d648b76785&application_id=1051243&site_id=vwd&application_name=news
(END) Dow Jones Newswires
May 19, 2020 13:00 ET (17:00 GMT)
